Meta-analysis of recurrence pattern after resection for pancreatic cancer.
Journal
The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
09
01
2019
revised:
06
04
2019
accepted:
04
06
2019
pubmed:
28
8
2019
medline:
9
4
2020
entrez:
28
8
2019
Statut:
ppublish
Résumé
Initial recurrence mapping of resected pancreatic ductal adenocarcinoma (PDAC) could help in stratifying patient subpopulations for optimal postoperative follow-up. The aim of this systematic review and meta-analysis was to investigate the initial recurrence patterns of PDAC and to correlate them with clinicopathological factors. MEDLINE and Web of Science databases were searched systematically for studies reporting first recurrence patterns after PDAC resection. Data were extracted from the studies selected for inclusion. Pooled odds ratios (ORs) and 95 per cent confidence intervals were calculated to determine the clinicopathological factors related to the recurrence sites. The weighted average of median overall survival was calculated. Eighty-nine studies with 17 313 patients undergoing PDAC resection were included. The weighted median rates of initial recurrence were 20·8 per cent for locoregional sites, 26·5 per cent for liver, 11·4 per cent for lung and 13·5 per cent for peritoneal dissemination. The weighted median overall survival times were 19·8 months for locoregional recurrence, 15·0 months for liver recurrence, 30·4 months for lung recurrence and 14·1 months for peritoneal dissemination. Meta-analysis revealed that R1 (direct) resection (OR 2·21, 95 per cent c.i. 1·12 to 4·35), perineural invasion (OR 5·19, 2·79 to 9·64) and positive peritoneal lavage cytology (OR 5·29, 3·03 to 9·25) were significantly associated with peritoneal dissemination as initial recurrence site. Low grade of tumour differentiation was significantly associated with liver recurrence (OR 4·15, 1·71 to 10·07). Risk factors for recurrence patterns after surgery could be considered for specific surveillance and treatments for patients with pancreatic cancer. El mapeo del patrón de recidiva inicial tras la resección de un adenocarcinoma ductal pancreático (pancreatic ductal adenocarcinoma, PDAC) podría ayudar a estratificar subpoblaciones de pacientes para un seguimiento postoperatorio óptimo. El objetivo de esta revisión sistemática con metaanálisis fue investigar los patrones de recidiva inicial de PDAC y correlacionarlos con factores clínico-patológicos. MÉTODOS: Se realizaron búsquedas sistemáticas en las bases de datos MEDLINE y Web of Science para seleccionar estudios que presentaran información sobre los patrones de recidiva inicial después de la resección del PDAC. Se extrajeron los datos de los estudios seleccionados para su inclusión en el metaanálisis. Se calcularon las razones de oportunidades agrupadas (pooled odds ratio, OR) y los i.c. del 95% para definir los factores clínico-patológicos relacionados con las localizaciones de la recidiva. Se estimó el promedio ponderado de la mediana de la supervivencia global. Se incluyeron 89 estudios con 17.313 pacientes a los que se realizó una resección por PDAC. Las tasas medias ponderadas de las localizaciones de la recidiva inicial fueron del 20,8% para la locorregional, 26,5% para las hepáticas, 11,4% para el pulmón y 13,5% para la diseminación peritoneal. La mediana ponderada de supervivencia global fue de 19,8 meses (locorregional), 15,0 meses (hígado), 30,4 meses (pulmón) y 14,1 meses (diseminación peritoneal). El metaanálisis demostró que la resección R1 (inicial) (OR 2,21, i.c. del 95% 1,12-4,35), la invasión perineural (OR 5,19; i.c. del 95% 2,79-9,64) y la positividad de la citología del lavado peritoneal (OR 5,29; i.c. del 95% 3,03-9,25) se asociaron significativamente con la diseminación peritoneal como localización de recidiva inicial. El bajo grado de diferenciación tumoral se asoció significativamente con la recidiva hepática (OR 4,15; i.c. del 95%: 1,71-10,07). CONCLUSIÓN: Se podrían tener en cuenta estos factores de riesgo de los patrones de recidiva tras la cirugía para realizar un seguimiento y tratamiento específicos en pacientes con cáncer de páncreas.
Sections du résumé
BACKGROUND
Initial recurrence mapping of resected pancreatic ductal adenocarcinoma (PDAC) could help in stratifying patient subpopulations for optimal postoperative follow-up. The aim of this systematic review and meta-analysis was to investigate the initial recurrence patterns of PDAC and to correlate them with clinicopathological factors.
METHODS
MEDLINE and Web of Science databases were searched systematically for studies reporting first recurrence patterns after PDAC resection. Data were extracted from the studies selected for inclusion. Pooled odds ratios (ORs) and 95 per cent confidence intervals were calculated to determine the clinicopathological factors related to the recurrence sites. The weighted average of median overall survival was calculated.
RESULTS
Eighty-nine studies with 17 313 patients undergoing PDAC resection were included. The weighted median rates of initial recurrence were 20·8 per cent for locoregional sites, 26·5 per cent for liver, 11·4 per cent for lung and 13·5 per cent for peritoneal dissemination. The weighted median overall survival times were 19·8 months for locoregional recurrence, 15·0 months for liver recurrence, 30·4 months for lung recurrence and 14·1 months for peritoneal dissemination. Meta-analysis revealed that R1 (direct) resection (OR 2·21, 95 per cent c.i. 1·12 to 4·35), perineural invasion (OR 5·19, 2·79 to 9·64) and positive peritoneal lavage cytology (OR 5·29, 3·03 to 9·25) were significantly associated with peritoneal dissemination as initial recurrence site. Low grade of tumour differentiation was significantly associated with liver recurrence (OR 4·15, 1·71 to 10·07).
CONCLUSION
Risk factors for recurrence patterns after surgery could be considered for specific surveillance and treatments for patients with pancreatic cancer.
ANTECEDENTES
El mapeo del patrón de recidiva inicial tras la resección de un adenocarcinoma ductal pancreático (pancreatic ductal adenocarcinoma, PDAC) podría ayudar a estratificar subpoblaciones de pacientes para un seguimiento postoperatorio óptimo. El objetivo de esta revisión sistemática con metaanálisis fue investigar los patrones de recidiva inicial de PDAC y correlacionarlos con factores clínico-patológicos. MÉTODOS: Se realizaron búsquedas sistemáticas en las bases de datos MEDLINE y Web of Science para seleccionar estudios que presentaran información sobre los patrones de recidiva inicial después de la resección del PDAC. Se extrajeron los datos de los estudios seleccionados para su inclusión en el metaanálisis. Se calcularon las razones de oportunidades agrupadas (pooled odds ratio, OR) y los i.c. del 95% para definir los factores clínico-patológicos relacionados con las localizaciones de la recidiva. Se estimó el promedio ponderado de la mediana de la supervivencia global.
RESULTADOS
Se incluyeron 89 estudios con 17.313 pacientes a los que se realizó una resección por PDAC. Las tasas medias ponderadas de las localizaciones de la recidiva inicial fueron del 20,8% para la locorregional, 26,5% para las hepáticas, 11,4% para el pulmón y 13,5% para la diseminación peritoneal. La mediana ponderada de supervivencia global fue de 19,8 meses (locorregional), 15,0 meses (hígado), 30,4 meses (pulmón) y 14,1 meses (diseminación peritoneal). El metaanálisis demostró que la resección R1 (inicial) (OR 2,21, i.c. del 95% 1,12-4,35), la invasión perineural (OR 5,19; i.c. del 95% 2,79-9,64) y la positividad de la citología del lavado peritoneal (OR 5,29; i.c. del 95% 3,03-9,25) se asociaron significativamente con la diseminación peritoneal como localización de recidiva inicial. El bajo grado de diferenciación tumoral se asoció significativamente con la recidiva hepática (OR 4,15; i.c. del 95%: 1,71-10,07). CONCLUSIÓN: Se podrían tener en cuenta estos factores de riesgo de los patrones de recidiva tras la cirugía para realizar un seguimiento y tratamiento específicos en pacientes con cáncer de páncreas.
Autres résumés
Type: Publisher
(spa)
El mapeo del patrón de recidiva inicial tras la resección de un adenocarcinoma ductal pancreático (pancreatic ductal adenocarcinoma, PDAC) podría ayudar a estratificar subpoblaciones de pacientes para un seguimiento postoperatorio óptimo. El objetivo de esta revisión sistemática con metaanálisis fue investigar los patrones de recidiva inicial de PDAC y correlacionarlos con factores clínico-patológicos. MÉTODOS: Se realizaron búsquedas sistemáticas en las bases de datos MEDLINE y Web of Science para seleccionar estudios que presentaran información sobre los patrones de recidiva inicial después de la resección del PDAC. Se extrajeron los datos de los estudios seleccionados para su inclusión en el metaanálisis. Se calcularon las razones de oportunidades agrupadas (pooled odds ratio, OR) y los i.c. del 95% para definir los factores clínico-patológicos relacionados con las localizaciones de la recidiva. Se estimó el promedio ponderado de la mediana de la supervivencia global.
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1590-1601Informations de copyright
© 2019 BJS Society Ltd Published by John Wiley & Sons Ltd.
Références
Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C et al. European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol 2017; 28: 1117-1123.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30.
Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg 2018; 267: 936-945.
Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389: 1011-1024.
Sperti C, Moletta L, Merigliano S. Multimodality treatment of recurrent pancreatic cancer: myth or reality? World J Gastrointest Oncol 2015; 7: 375-382.
Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 2009; 35: 600-604.
Groot VP, Gemenetzis G, Blair AB, Ding D, Javed AA, Burkhart RA et al. Implications of the pattern of disease recurrence on survival following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg Oncol 2018; 25: 2475-2483.
Strobel O, Hartwig W, Hackert T, Hinz U, Berens V, Grenacher L et al. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol 2013; 20: 964-972.
Hackert T, Niesen W, Hinz U, Tjaden C, Strobel O, Ulrich A et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol 2017; 43: 358-363.
Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017; 15: 1028-1061.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100.
Higgins JPT, Green S (eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration: Copenhagen.
Goossen K, Tenckhoff S, Probst P, Grummich K, Mihaljevic AL, Buchler MW et al. Optimal literature search for systematic reviews in surgery. Langenbecks Arch Surg 2018; 403: 119-129.
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
Sterne JA, Hernan MA, Reeves BC, Savović J, Berkman ND, Viswanathan M et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919.
Yamada D, Eguchi H, Iwagami Y, Asaoka T, Noda T, Kawamoto K et al. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy. Surg Today 2018; 48: 952-962.
Wang Y, Xu Y, Zheng Y, Bao Y, Wang P. Postoperative hepatic arterial infusion chemotherapy improved survival of pancreatic cancer after radical pancreatectomy: a retrospective study. Onco Targets Ther 2018; 11: 903-907.
Walston S, Salloum J, Grieco C, Wuthrick E, Diaz DA, Barney C et al. Identifying clinical factors which predict for early failure patterns following resection for pancreatic adenocarcinoma in patients who received adjuvant chemotherapy without chemoradiation. Am J Clin Oncol 2018; 41: 1185-1192.
Nakayama Y, Sugimoto M, Gotohda N, Konishi M, Takahashi S. Efficacy of completion pancreatectomy for recurrence of adenocarcinoma in the remnant pancreas. J Surg Res 2018; 221: 15-23.
Mizumoto T, Toyama H, Asari S, Terai S, Mukubo H, Yamashita H et al. Pathological and radiological splenic vein involvement are predictors of poor prognosis and early liver metastasis after surgery in patients with pancreatic adenocarcinoma of the body and tail. Ann Surg Oncol 2018; 25: 638-646.
Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg 2019; 269: 1154-1162.
Groot VP, Daamen LA, Hagendoorn J, Borel Rinkes IHM, van Santvoort HC, Molenaar IQ. Use of imaging during symptomatic follow-up after resection of pancreatic ductal adenocarcinoma. J Surg Res 2018; 221: 152-160.
Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg 2019; 270: 340-347.
Ariake K, Motoi F, Shimomura H, Mizuma M, Maeda S, Terao C et al. 18-Fluorodeoxyglucose positron emission tomography predicts recurrence in resected pancreatic ductal adenocarcinoma. J Gastrointest Surg 2018; 22: 279-287.
Zheng B, Ohuchida K, Yan Z, Okumura T, Ohtsuka T, Nakamura M. Primary recurrence in the lung is related to favorable prognosis in patients with pancreatic cancer and postoperative recurrence. World J Surg 2017; 41: 2858-2866.
Yamada S, Fujii T, Takami H, Hayashi M, Iwata N, Kanda M et al. Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. Surgery 2017; 162: 784-791.
Watanabe Y, Nishihara K, Niina Y, Kudo Y, Kurata K, Okayama T et al. Patients with lung recurrence after curative resection for pancreatic ductal adenocarcinoma have a better prognosis than those with recurrence at other sites. J Pancreas 2017; 18: 54-61.
Shin SH, Kim HJ, Hwang DW, Lee JH, Song KB, Jun E et al. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: a prospective cohort study. Oncotarget 2017; 8: 17945-17959.
Satoi S, Yanagimoto H, Yamamoto T, Ohe C, Miyasaka C, Uemura Y et al. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy. Surg Today 2017; 47: 84-91.
Nishio K, Kimura K, Amano R, Yamazoe S, Ohrira G, Nakata B et al. Preoperative predictors for early recurrence of resectable pancreatic cancer. World J Surg Oncol 2017; 15: 16.
Nakano Y, Kitago M, Shinoda M, Abe Y, Yagi H, Hibi T et al. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. Cancer Med 2017; 6: 2278-2286.
Nagakawa Y, Hosokawa Y, Nakayama H, Sahara Y, Takishita C, Nakajima T et al. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement. Cancer Chemother Pharmacol 2017; 79: 951-957.
Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Bui JL, Yuan C et al. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Br J Cancer 2017; 117: 1874-1882.
Lovecek M, Skalicky P, Chudacek J, Szkorupa M, Svebisova H, Lemstrova R et al. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: retrospective study and review of the literature. World J Gastroenterol 2017; 23: 6420-6428.
Kim S, Itchins M, Arena J, Nahm C, Pavlakis N, Clarke S et al. Patterns and determinants of recurrence for pancreatic ductal adenocarcinoma after resection. J Pancreas 2017; 18: 458-464.
Hosokawa Y, Nagakawa Y, Sahara Y, Takishita C, Katsumata K, Tsuchida A. Serum SPan-1 is a significant risk factor for early recurrence of pancreatic cancer after curative resection. Dig Surg 2017; 34: 125-132.
Hoshimoto S, Hishinuma S, Shirakawa H, Tomikawa M, Ozawa I, Wakamatsu S et al. Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer. Eur J Surg Oncol 2017; 43: 1068-1075.
Hoshimoto S, Hishinuma S, Shirakawa H, Tomikawa M, Ozawa I, Hoshi N et al. Prognostic significance of intraoperative peritoneal washing cytology for patients with potentially resectable pancreatic ductal adenocarcinoma. Pancreatology 2017; 17: 109-114.
Ariake K, Motoi F, Ohtsuka H, Fukase K, Masuda K, Mizuma M et al. Predictive risk factors for peritoneal recurrence after pancreatic cancer resection and strategies for its prevention. Surg Today 2017; 47: 1434-1442.
Abe T, Ohuchida K, Endo S, Ookubo F, Mori Y, Nakata K et al. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer. Surgery 2017; 161: 951-958.
Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 2016; 388: 248-257.
Mierke F, Hempel S, Distler M, Aust DE, Saeger HD, Weitz J et al. Impact of portal vein involvement from pancreatic cancer on metastatic pattern after surgical resection. Ann Surg Oncol 2016; 23(Suppl 5): 730-736.
Labori KJ, Katz MH, Tzeng CW, Bjornbeth BA, Cvancarova M, Edwin B et al. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - a population-based cohort study. Acta Oncol 2016; 55: 265-277.
Kruger S, Haas M, Burger PJ, Ormanns S, Modest DP, Westphalen CB et al. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Pancreatology 2016; 16: 593-598.
Kim HJ, Lee WJ, Kang CM, Hwang HK, Bang SM, Song SY et al. Risk factors associated with loco-regional failure after surgical resection in patients with resectable pancreatic cancer. PLoS One 2016; 11: e0157196.
Barnes C, Aldakkak M, Christians K, Ritch PS, George B, Johnston F et al. Impact of treatment sequencing on sites of first recurrence in patients with localized pancreatic cancer. Gastroenterology 2016; 150: S1213-S1213.
Baekelandt BM, Hjermstad MJ, Nordby T, Fagerland MW, Kure EH, Heiberg T et al. Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma. HPB 2016; 18: 247-254.
Yamashita K, Miyamoto A, Hama N, Asaoka T, Maeda S, Omiya H et al. Survival impact of pulmonary metastasis as recurrence of pancreatic ductal adenocarcinoma. Dig Surg 2015; 32: 464-471.
Wangjam T, Zhang Z, Zhou XC, Lyer L, Faisal F, Soares KC et al. Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. Oncotarget 2015; 6: 36 903-36 910.
Strom TJ, Klapman JB, Springett GM, Meredith KL, Hoffe SE, Choi J et al. Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage. Surg Endosc 2015; 29: 3273-3281.
Sho M, Murakami Y, Motoi F, Satoi S, Matsumoto I, Kawai M et al. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. J Gastroenterol 2015; 50: 694-702.
Sherman WH, Chu K, Chabot J, Allendorf J, Schrope BA, Hecht E et al. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma. Cancer 2015; 121: 673-680.
Patel AA, Nagarajan S, Scher ED, Schonewolf CA, Balasubramanian S, Poplin E et al. Early vs. late chemoradiation therapy and the postoperative interval to adjuvant therapy do not correspond to local recurrence in resected pancreatic cancer. Pancreat Disord Ther 2015; 5: 151.
Matsumoto I, Murakami Y, Shinzeki M, Asari S, Goto T, Tani M et al. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: a multi-center retrospective study. Pancreatology 2015; 15: 674-680.
Liu L, Katz MH, Lee SM, Fischer LK, Prakash L, Parker N et al. Superior mesenteric artery margin of posttherapy pancreaticoduodenectomy and prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol 2015; 39: 1395-1403.
Kim BH, Kim K, Chie EK, Jang JY, Kim SW, Han SW et al. Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma. Cancer Res Treat 2015; 47: 274-281.
Yamamoto Y, Ikoma H, Morimura R, Konishi H, Murayama Y, Komatsu S et al. Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in the prognosis. Pancreatology 2014; 14: 524-529.
Papavasiliou P, Hoffman JP, Cohen SJ, Meyer JE, Watson JC, Chun YS. Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. HPB 2014; 16: 34-39.
O'Reilly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg 2014; 260: 142-148.
Gangi A, Menon VG, Sheckley M, Tuli R, Hendifar AE, Wachsman A et al. Recurrence of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: is there a role for locoregional treatment? J Clin Oncol 2014; 32(Suppl 3): 329-329.
Sugiura T, Uesaka K, Mihara K, Sasaki K, Kanemoto H, Mizuno T et al. Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer. Surgery 2013; 154: 1078-1086.
Patel A, Schonewolf C, Balasubramanian S, Moss R, Melstrom L, Haffty BG et al. Postoperative interval between surgery and initiation of adjuvant therapy corresponds to local recurrence in resected pancreatic cancer. Int J Radiat Oncol Biol Phys 2013; 87: S313-S313.
Nordby T, Hugenschmidt H, Fagerland MW, Ikdahl T, Buanes T, Labori KJ. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival. Eur J Surg Oncol 2013; 39: 559-566.
Chen KTK, Singla S, Papavasiliou P, Arrangoiz R, Gaughan JP, Hoffman JP. Patterns of recurrence and outcomes in pancreatic cancer. J Clin Oncol 2013; 31: 234.
Yoshioka R, Saiura A, Koga R, Arita J, Takemura N, Ono Y et al. The implications of positive peritoneal lavage cytology in potentially resectable pancreatic cancer. World J Surg 2012; 36: 2187-2191.
Wang J, Estrella JS, Peng L, Rashid A, Varadhachary GR, Wang H et al. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2012; 118: 3801-3811.
Tzeng CW, Fleming JB, Lee JE, Wang X, Pisters PW, Vauthey JN et al. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB 2012; 14: 365-372.
Thomas RM, Truty MJ, Nogueras-Gonzalez GM, Fleming JB, Vauthey JN, Pisters PW et al. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg 2012; 16: 1696-1704.
Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Sasaki K, Furukawa H et al. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg 2012; 16: 977-985.
Murata Y, Mizuno S, Kishiwada M, Hamada T, Usui M, Sakurai H et al. Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4. Pancreas 2012; 41: 130-136.
Katz MH, Wang H, Balachandran A, Bhosale P, Crane CH, Wang X et al. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg 2012; 16: 68-79.
Gnerlich JL, Luka SR, Deshpande AD, Dubray BJ, Weir JS, Carpenter DH et al. Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg 2012; 147: 753-760.
Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer 2012; 118: 3182-3190.
Bachet JB, Maréchal R, Demetter P, Bonnetain F, Couvelard A, Svrcek M et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol 2012; 23: 2327-2335.
Takahashi S, Kinoshita T, Konishi M, Gotohda N, Kato Y, Kinoshita T et al. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. J Hepatobiliary Pancreat Sci 2011; 18: 567-574.
Sho M, Tanaka T, Yamada T, Nomi T, Akahori T, Doh J et al. Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. J Hepatobiliary Pancreat Sci 2011; 18: 235-240.
Shimada K, Nara S, Esaki M, Sakamoto Y, Kosuge T, Hiraoka N. Intrapancreatic nerve invasion as a predictor for recurrence after pancreaticoduodenectomy in patients with invasive ductal carcinoma of the pancreas. Pancreas 2011; 40: 464-468.
Miller SM, Ali AN, Mick R, Moghanaki D, Furth EE, Sohal D et al. Patterns of failure after trimodality therapy for pancreatic and duodenal cancers. Int J Radiat Oncol Biol Phys 2011; 81: S336-S336.
Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E et al. Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial. Ann Surg Oncol 2011; 18: 3615-3622.
Jamieson NB, Foulis AK, Oien KA, Dickson EJ, Imrie CW, Carter R et al. Peripancreatic fat invasion is an independent predictor of poor outcome following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. J Gastrointest Surg 2011; 15: 512-524.
Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 2010; 28: 4450-4456.
Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101: 908-915.
Tani M, Kawai M, Miyazawa M, Hirono S, Ina S, Nishioka R et al. Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma. Langenbecks Arch Surg 2009; 394: 249-253.
Showalter TN, Rao AS, Rani Anne P, Rosato FE, Rosato EL, Andrel J et al. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis. Ann Surg Oncol 2009; 16: 2116-2122.
Satoi S, Yanagimoto H, Toyokawa H, Takahashi K, Matsui Y, Kitade H et al. Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas 2009; 38: 282-288.
Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009; 16: 836-847.
Hattangadi JA, Hong TS, Yeap BY, Mamon HJ. Results and patterns of failure in patients treated with adjuvant combined chemo-radiation therapy for resected pancreatic adenocarcinoma. Cancer 2009; 115: 3640-3650.
Desai S, Ben-Josef E, Griffith KA, Simeone D, Greenson JK, Francis IR et al. Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer. Int J Radiat Oncol Biol Phys 2009; 75: 1450-1455.
Asiyanbola B, Gleisner A, Herman JM, Choti MA, Wolfgang CL, Swartz M et al. Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg 2009; 13: 752-759.
Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3487-3495.
Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 2008; 247: 456-462.
Kinsella TJ, Seo Y, Willis J, Stellato TA, Siegel CT, Harpp D et al. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol 2008; 31: 446-453.
Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3496-3502.
Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007; 246: 52-60.
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277.
Shimada K, Sakamoto Y, Sano T, Kosuge T. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery 2006; 139: 288-295.
Massucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol 2006; 13: 1201-1208.
Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA et al. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer 2006; 95: 260-265.
Shibata K, Matsumoto T, Yada K, Sasaki A, Ohta M, Kitano S. Factors predicting recurrence after resection of pancreatic ductal carcinoma. Pancreas 2005; 31: 69-73.
Moutardier V, Turrini O, Huiart L, Viret F, Giovannini MH, Magnin V et al. A reappraisal of preoperative chemoradiation for localized pancreatic head ductal adenocarcinoma in a 5-year single-institution experience. J Gastrointest Surg 2004; 8: 502-510.
Meszoely IM, Lee JS, Watson JC, Meyers M, Wang H, Hoffman JP. Peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreas. Am Surg 2004; 70: 208-213.
Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8: 123-132.
Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 2015; 12: 319-334.
Downs-Canner S, Zenati M, Boone BA, Varley PR, Steve J, Hogg ME et al. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas. J Surg Oncol 2015; 112: 80-85.
Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017; 35: 2324-2328.
Takaori K, Bassi C, Biankin A, Brunner TB, Cataldo I, Campbell F et al. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology 2016; 16: 14-27.
Seufferlein T, Bachet JB, Van Cutsem E, Rougier P; ESMO Guidelines Working Group. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 7): vii33-vii40.
Decoster C, Gilabert M, Autret A, Turrini O, Oziel-Taieb S, Poizat F et al. Heterogeneity of metastatic pancreatic adenocarcinoma: lung metastasis show better prognosis than liver metastasis - a case control study. Oncotarget 2016; 7: 45 649-45 655.